Impact of Age on Outcomes in Endometrial Cancer
In an analysis of data from the PORTEC-1, -2, and -3 trials, older age was found to be associated with more aggressive tumor features and poorer outcomes in women with endometrial cancer.
In an analysis of data from the PORTEC-1, -2, and -3 trials, older age was found to be associated with more aggressive tumor features and poorer outcomes in women with endometrial cancer.
Arndt Vogel, MD, on the final overall survival data for camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.
Suresh S. Ramalingam, MD, FACP, FASCO, discusses findings with osimertinib after definitive chemoradiotherapy in unresectable EGFR-mutated NSCLC.
The OncoAlert Newsletter is now out for June 23-29, 2023
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Ahmad A. Tarhini Departments of Cutaneous Oncology and Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL Ahmad A. Tarhini, Tingyi Li, Sandra…
An abstract is unavailable.
Kamran A. Ahmed H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL Kamran A. Ahmed, Youngchul Kim, Michelle DeJesus, Daniel Eli Oliver, Matthew Mills,…
Arndt Vogel, MD, on the final overall survival data for camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.
The OncoAlert Newsletter is now out for June 23-29, 2023
Arshit Narang Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT Arshit Narang, Ryon P Graf, Georges Gebrael, Chadi Hage Chehade, Gerald…